Older Cancer Patients Heavily Use Health Care Services

This article originally appeared here.
Share this content:
Older Cancer Patients Heavily Use Health Care Services
Older Cancer Patients Heavily Use Health Care Services

WEDNESDAY, Sept. 2, 2015 (HealthDay News) -- Older patients with acute myeloid leukemia (AML) are intense users of health care services and rarely use palliative care and hospice services, according to a study published in the August issue of Cancer.

Areej R. El-Jawahri, M.D., from Massachusetts General Hospital in Boston, and colleagues retrospectively analyzed health care utilization and end-of-life care in 330 consecutive older patients diagnosed with AML between May 1, 2005, and December 23, 2011.

The researchers found that the median number of hospitalizations for the entire cohort was 4.2. For patients who died, 28.3 percent of their life after diagnosis was spent in the hospital and 13.8 percent attending outpatient clinic appointments. Over two years of follow-up, the majority of patients (87.9 percent) died, although only a minority received palliative care (16.2 percent) or hospice (23.1 percent) services. Sixty-one percent died in the hospital. Patients who received intensive induction therapy (cytarabine/anthracycline combination versus single-agent therapy) and who ultimately died spent 30 percent more of their life after diagnosis in the hospital (P < 0.0001) and were less likely to receive hospice services (odds ratio, 0.45; P = 0.05).

"The current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »